Mineralys Therapeutics (MLYS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Mineralys Therapeutics (MLYS) is Neutral.

The composite score behind that read is -0.18, weighing +0.21 of bullish evidence against -0.24 bearish.

Mineralys Therapeutics last closed at $23.30, -1.40% on the session.

Against the IVW growth benchmark the position is -2.32% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

4 graded predictions for MLYS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Mineralys Therapeutics in the 16th percentile on return on equity, where 100 is best.

Mineralys Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $2.09B.

StockMap tracks Mineralys Therapeutics as the 81st largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Mineralys Therapeutics ranks 140th of 344 in the group, against a group median of -0.21.